Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

Novartis has made a takeover approach for rare disease-focused biotech Avidity Biosciences, as Big Pharma continues to hunt ...

We recently published 10 Stocks With Easy 15-30% Upside. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing ...

Avidity Biosciences ( NASDAQ: RNA) quickly soared 20% after a report that Novartis ( NYSE: NVS) made a takeover approach for the rare-disease maker.

Swiss pharmaceutical giant Novartis is exploring a potential acquisition of U.S. biotech firm Avidity Biosciences, according ...

Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech ...

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

--Novartis made a takeover approach for Avidity Biosciences, a biotechnology company that specializes in rare diseases with a market value of $5.8 billion, the Financial Times reports, citing unnamed ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, FT reported.

This summary covers recent developments in health, including Novo Nordisk filing lawsuits against semaglutide compounders, ...